Statement of Changes in Beneficial Ownership (4)
March 16 2020 - 4:11PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
WEAVER GREGORY L |
2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc.
[
ELOX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) FORMER CHIEF FINANCIAL OFFICER |
(Last)
(First)
(Middle)
C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/15/2020 |
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/15/2020 | | M | | 3750 | A | $0 (1) | 11517 | D | |
Common Stock | 3/15/2020 | | F | | 1086 | D | $2.85 | 10431 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Restricted Stock Units | (1)(2) | 3/15/2020 | | M | | | 3750 | (1) | (1) | Common Stock | 3750 | $0 (3) | 0 (4) | D | |
Explanation of Responses: |
(1) | The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. |
(2) | Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
(3) | The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. |
(4) | As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
WEAVER GREGORY L C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET WALTHAM, MA 02451 |
|
|
| FORMER CHIEF FINANCIAL OFFICER |
Signatures
|
/s/ Neil S. Belloff, Attorney-in-Fact | | 3/16/2020 |
**Signature of Reporting Person | Date |
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Sep 2023 to Sep 2024